关键词: 慢性乙型肝炎, 阿德福韦酯, HBeAg阳性

Abstract: Objective This study assessed the safety and efficacy of adefovir dipivoxil（ADV）in treatment of patients with chronic hepatitis B and lamivudine-resistant hepatitis B virus（HBV）. Methods One hundred and one hepatitis B e-antigen（HBeAg）-positive na■ve patients（69 cases）and lamivudine-resistant HBV patients（32 cases）were treated with adefovir dipivoxil 10mg daily. The efficacy was evaluated until at 144th month（the administrated end point）and then continuously at 240th month. Results At the 144th month，the rates of ALT normalization were 91.3% and 90.6% in na■ve group and lamivudine-resistant group，respectively；the negative rates of HBV-DNA were 88.4% and 84.3%，respectively；the negative rates HBeAg were 34.7% and 28.1%，respectively；the seroconversion rates of HBeAg/HBeAb were 55.5% and 53.1%，respectively，and the seroconversion rates of HBsAg/HBsAb were 7.2% and 6.3%，respectively. There was no significant difference between the two groups（P>0.05）. The blood routine，urine routine and renal functions whether in the administered period or during the follow-up had no abnormal findings related to ADV. Conclusions Adefovir dipivoxil could effectively inhibit HBV replication，normalize ALT and enhance transformation from HBeAg to HBeAb for cases with naive patients and lamivudine-resistant patients． It is safe and has a good tolerance．

Key words: Hepatitis B, Adefovir dipivoxil, HBeAg positive